NTRA Stock — Natera Inc.

Natera Inc. (NTRA)

Updated October 16, 2026.

NTRA is a Stock. Total return is 1630.2% over the past 11.3 years, 1287.5 points ahead of SPY at 342.7%.

Natera is a diagnostics company that develops and commercializes molecular testing services, including blood-based and tissue-based tests for cancer monitoring and recurrence detection, prenatal screening, carrier screening, transplant rejection assessment, and hereditary cancer risk evaluation. The company does not currently pay distributions. Natera serves laboratories, medical centers, physician practices, and pharmaceutical companies through direct sales and distribution partners.

NTRA performance versus SPY

Price and return data through 2026-10-16.

Total return is 1630.2% over the past 11.3 years, 1287.5 points ahead of SPY at 342.7%. Over the past year its total return — price change plus distributions reinvested — is 117.9%. Its deepest 1-year drawdown was 28.2%.

NTRA key facts

Asset type

Stock

Asset class

Equity

Inception date

07/02/2015

Distribution frequency

None

Last close

$393.44 (as of 2026-10-16)

Market cap

$56,712,082,245

Average volume

1581430.0

Beta

1.499

Payout ratio

0.0%

Forward P/E

5000.0

EPS

$-1.35

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NTRA risks and drawbacks

The deepest 1-year drawdown on record here is 28.2%.

Who may consider NTRA — and who may not

It is a weaker fit for investors who need monthly cash flow (NTRA does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on NTRA

• ETFs holding NTRA
• All tickers starting with N

Tagged: Healthcare.

Frequently asked questions